Global Patent Index - EP 0938334 A4

EP 0938334 A4 20041215 - IMPROVED METHOD OF TREATING IMMUNE CELL MEDIATED SYSTEMIC DISEASES

Title (en)

IMPROVED METHOD OF TREATING IMMUNE CELL MEDIATED SYSTEMIC DISEASES

Title (de)

VERBESSERTES VERFAHREN ZUR BEHANDLUNG VON DURCH IMMUNZELLEN VERMITTELTEN SYSTEMISCHEN ERKRANKUNGEN

Title (fr)

METHODE AMELIOREE DE TRAITEMENT DE MALADIES DE L'ORGANISME INDUITES PAR DES CELLULES IMMUNES

Publication

EP 0938334 A4 20041215 (EN)

Application

EP 97936109 A 19970725

Priority

  • US 9712600 W 19970725
  • US 2247296 P 19960726

Abstract (en)

[origin: WO9804281A1] An improved method of treating immune cell mediated systemic diseases, particularly T and B cell mediated diseases, is provided by increasing the systemic exposure, or bioavailibility, of a therapeutic protein. Such therapeutic protein is selected from the group consisting of a monoclonal antibody, a soluble receptor and a soluble ligand which binds to an antigen expressed on the surface of an immune cell.

IPC 1-7

A61K 39/00; A61K 39/395; C07K 14/00; C07K 14/705; C07K 16/00

IPC 8 full level

C12N 15/02 (2006.01); A61K 38/00 (2006.01); A61K 38/17 (2006.01); A61K 39/395 (2006.01); A61P 11/06 (2006.01); A61P 17/06 (2006.01); A61P 29/00 (2006.01); A61P 37/02 (2006.01); C07K 14/705 (2006.01); C07K 16/28 (2006.01); C12P 21/08 (2006.01)

CPC (source: EP)

A61K 38/177 (2013.01); A61K 38/1774 (2013.01); A61P 11/06 (2017.12); A61P 17/06 (2017.12); A61P 29/00 (2017.12); A61P 37/02 (2017.12); C07K 16/2803 (2013.01); C07K 16/2812 (2013.01); C07K 16/2827 (2013.01); C07K 16/2878 (2013.01); A01K 2217/05 (2013.01)

Citation (search report)

  • [PX] WO 9709351 A1 19970313 - IDEC PHARMA CORP [US]
  • [X] KAINE J ET AL: "RESULTS OF A MULTI-DOSE PROTOCOL 7002 USING AN IMMUNOMODULATING NON-DEPLETING PRIMATIZEDTM ANTI-CD4 MONOCLONAL ANTIBODY IN RHEUMATOID ARTHRITIS (RA)", ARTHRITIS AND RHEUMATISM, LIPPINCOTT, PHILADELPHIA, US, vol. 38, no. 9, SUPPL, 21 November 1995 (1995-11-21), pages S185,AN195, XP001095999, ISSN: 0004-3591
  • [X] MORELAND L W ET AL: "TREATING RHEUMATOID ARTHRITIS WITH A NON-DEPLETING ANTI-CD4 MONOCLONAL ANTIBODY", JOURNAL OF INVESTIGATIVE MEDICINE, AMERICAN FEDERATION FOR CLINICAL RESEARCH,, US, vol. 43, no. SUPPL 2, 5 May 1995 (1995-05-05), pages 362A, XP001106168, ISSN: 1081-5589
  • [X] YOCUM D E ET AL: "CLINICAL AND IMMUNOPHARMACOLOGIC EFFECTS OF PRIMATIZEDTM IDEC-CE9.1, AN ANTI-CD4 MONOCLONALANTIBODY IN A PHASE I TRIAL IN ACTIVE RHEUMATOID ARTHRITIS", JOURNAL OF INVESTIGATIVE MEDICINE, AMERICAN FEDERATION FOR CLINICAL RESEARCH,, US, vol. 43, no. SUPPL 2, April 1995 (1995-04-01), pages 253A, XP001095992, ISSN: 1081-5589
  • [X] EMMRICH F ET AL: "An anti-CD4 antibody for treatment of chronic inflammatory arthritis.", AGENTS AND ACTIONS. SUPPLEMENTS. 1991, vol. 32, 1991, pages 165 - 170, XP001182725, ISSN: 0379-0363
  • [X] BATA-CSORGO Z ET AL: "Intralesional T-lymphocyte activation as a mediator of psoriatic epidermal hyperplasia.", THE JOURNAL OF INVESTIGATIVE DERMATOLOGY. JUL 1995, vol. 105, no. 1 Suppl, July 1995 (1995-07-01), pages 89S - 94S, XP009034211, ISSN: 0022-202X
  • [X] THIVOLET J ET AL: "Immunointervention in psoriasis with anti-CD4 antibodies.", INTERNATIONAL JOURNAL OF DERMATOLOGY. MAY 1994, vol. 33, no. 5, May 1994 (1994-05-01), pages 327 - 332, XP009034206, ISSN: 0011-9059
  • [X] GAVETT S H ET AL: "Depletion of murine CD4+ T lymphocytes prevents antigen-induced airway hyperreactivity and pulmonary eosinophilia.", AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY. JUN 1994, vol. 10, no. 6, June 1994 (1994-06-01), pages 587 - 593, XP009034204, ISSN: 1044-1549
  • See references of WO 9804281A1

Designated contracting state (EPC)

BE CH DE ES FR GB IT LI NL

DOCDB simple family (publication)

WO 9804281 A1 19980205; EP 0938334 A1 19990901; EP 0938334 A4 20041215; JP 2000516594 A 20001212

DOCDB simple family (application)

US 9712600 W 19970725; EP 97936109 A 19970725; JP 50889298 A 19970725